Show simple item record

dc.contributor.authorChabloz, A
dc.contributor.authorSchaefer, JV
dc.contributor.authorKozieradzki, I
dc.contributor.authorCronin, SJF
dc.contributor.authorStrebinger, D
dc.contributor.authorMacaluso, F
dc.contributor.authorWald, J
dc.contributor.authorRabbitts, TH
dc.contributor.authorPlückthun, A
dc.contributor.authorMarlovits, TC
dc.contributor.authorPenninger, JM
dc.date.accessioned2020-08-27T09:02:58Z
dc.date.issued2020-07-03
dc.identifier.citationCommunications biology, 2020, 3 (1), pp. 342 - ?
dc.identifier.issn2399-3642
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4031
dc.identifier.eissn2399-3642
dc.identifier.doi10.1038/s42003-020-1072-4
dc.description.abstractProtein-based affinity reagents (like antibodies or alternative binding scaffolds) offer wide-ranging applications for basic research and therapeutic approaches. However, whereas small chemical molecules efficiently reach intracellular targets, the delivery of macromolecules into the cytosol of cells remains a major challenge; thus cytosolic applications of protein-based reagents are rather limited. Some pathogenic bacteria have evolved a conserved type III secretion system (T3SS) which allows the delivery of effector proteins into eukaryotic cells. Here, we enhance the T3SS of an avirulent strain of Salmonella typhimurium to reproducibly deliver multiple classes of recombinant proteins into eukaryotic cells. The efficacy of the system is probed with both DARPins and monobodies to functionally inhibit the paradigmatic and largely undruggable RAS signaling pathway. Thus, we develop a bacterial secretion system for potent cytosolic delivery of therapeutic macromolecules.
dc.formatElectronic
dc.format.extent342 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleSalmonella-based platform for efficient delivery of functional binding proteins to the cytosol.
dc.typeJournal Article
dcterms.dateAccepted2020-06-11
rioxxterms.versionofrecord10.1038/s42003-020-1072-4
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-07-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCommunications biology
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.publication-statusPublished
pubs.volume3
pubs.embargo.termsNot known
icr.researchteamChromosomal Translocations and Intracellular Antibody Therapeutics
dc.contributor.icrauthorRabbitts, Terence


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0